Lisata Therapeutics, Inc. (LSTA)

Lisata Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1	-	-	-	-
Gross Profit	1	-	-	-	-
Selling, General & Admin	12.08	12.97	14.14	11.47	9.89
Research & Development	11.33	12.73	13.07	17.58	9.25
Operating Expenses	23.41	25.71	27.21	29.05	19.15
Operating Income	-22.41	-25.71	-27.21	-29.05	-19.15
Interest & Investment Income	1.88	2.72	1.05	0.15	0.13
Other Non Operating Income (Expenses)	-0.36	-0.29	-0.06	-0.08	-
EBT Excluding Unusual Items	-20.88	-23.27	-26.21	-28.97	-19.01
Gain (Loss) on Sale of Assets	0.1	0.1	-0.1	-	-
Pretax Income	-20.78	-23.17	-56.7	-28.97	-19.01
Income Tax Expense	-0.8	-2.33	-2.48	-1.51	-10.87
Earnings From Continuing Operations	-19.99	-20.84	-54.23	-27.47	-8.14
Net Income to Company	-19.99	-20.84	-54.23	-27.47	-8.14
Minority Interest in Earnings	-	-	-	-	-0.01
Net Income	-19.99	-20.84	-54.23	-27.47	-8.15
Net Income to Common	-19.99	-20.84	-54.23	-27.47	-8.15
Shares Outstanding (Basic)	8	8	5	4	1
Shares Outstanding (Diluted)	8	8	5	4	1
Shares Change (YoY)	3.17%	55.85%	40.46%	258.29%	49.54%
EPS (Basic)	-2.40	-2.58	-10.47	-7.45	-7.92
EPS (Diluted)	-2.40	-2.58	-10.47	-7.45	-7.92
Free Cash Flow	-19.36	-20.03	-21.46	-22.31	-8.84
Free Cash Flow Per Share	-2.32	-2.48	-4.14	-6.05	-8.59
Gross Margin	100.00%	-	-	-	-
Operating Margin	-2240.90%	-	-	-	-
Profit Margin	-1998.50%	-	-	-	-
Free Cash Flow Margin	-1935.60%	-	-	-	-
EBITDA	-22.24	-25.52	-27.14	-29	-19.08
D&A For EBITDA	0.17	0.19	0.07	0.06	0.06
EBIT	-22.41	-25.71	-27.21	-29.05	-19.15

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q